Spearmint
Mentha spicata
Evidence Rating
Confidence Level
Traditions
Last Updated
Summary
Spearmint (Mentha spicata) tea has demonstrated significant anti-androgenic effects in women with PCOS and hirsutism across several randomized controlled trials, consistently reducing free testosterone levels while increasing LH, FSH, and estradiol. The key active compounds include rosmarinic acid (the dominant polyphenol, comprising up to 88% of total phenolics), the monoterpene carvone, and limonene. Spearmint is notable for being a widely available, food-grade herb with a favorable safety profile and genuine therapeutic potential -- a rarity in phytotherapy. Emerging evidence from double-blind RCTs also supports the use of high-polyphenol spearmint extract (900 mg/day) for cognitive enhancement, particularly working memory and attention in older adults and active populations.
Regulatory Status
| Regulatory Body | Status |
|---|---|
| Commission E (Germany) | — |
| ESCOP (European) | — |
| EMA/HMPC (EU) | — |
Metadata
| Field | Detail |
|---|---|
| Common Names (English) | Spearmint, Garden Mint, Common Mint, Lamb Mint, Our Lady’s Mint |
| Common Names (German) | Grüne Minze, Krauseminze, Ährenminze |
| Common Names (French) | Menthe verte, Menthe douce, Menthe en épi |
| Botanical Name | Mentha spicata L. (syn. Mentha viridis) |
| Plant Family | Lamiaceae (Labiatae) |
| Part Used | Leaf and aerial parts (Menthae crispae folium) |
| Evidence Quality Rating | Moderate — several small RCTs with consistent hormonal findings; no formal European monograph for medicinal use; growing evidence base for anti-androgenic and cognitive applications |
Approved Indications
Commission E (Germany)
- No Commission E monograph for spearmint (Mentha spicata) as a medicinal herb
- Note: Commission E has a positive monograph for peppermint (Mentha x piperita) — these are distinct species with different phytochemistry and indications
ESCOP
- No ESCOP monograph for spearmint
- ESCOP monographs exist for peppermint leaf and peppermint oil — not applicable to spearmint
EMA/HMPC
- No EMA/HMPC monograph for spearmint (Mentha spicata)
- EMA has well-established and traditional use monographs for peppermint — these do not extend to spearmint
- Spearmint lacks the high menthol content that defines peppermint’s pharmacological profile
Important Distinction from Peppermint
Spearmint and peppermint are frequently confused but are pharmacologically distinct:
| Feature | Spearmint (M. spicata) | Peppermint (M. x piperita) |
|---|---|---|
| Key volatile | Carvone (22—73%) | Menthol (30—55%) |
| Menthol content | Minimal (<1%) | High (30—55%) |
| European monographs | None | Commission E, ESCOP, EMA |
| Primary clinical use | Anti-androgenic (PCOS) | Digestive (IBS), topical analgesic |
| Rosmarinic acid | Very high | Moderate |
Spearmint’s therapeutic identity in modern research is defined by its anti-androgenic effects and high polyphenol content, neither of which is shared with peppermint.
Conditions Treated
Primary (Clinical Evidence from RCTs)
- Hyperandrogenism in PCOS: Reduction of free testosterone, normalization of LH/FSH ratio, increase in estradiol
- Hirsutism (idiopathic and PCOS-related): Hormonal improvement demonstrated; clinical hair reduction requires longer treatment duration than studied
- Androgenic symptoms in women: Acne, oily skin, and hormonal hair growth linked to elevated androgens (extrapolated from hormonal data)
Secondary (Supported by Clinical Trials)
- Cognitive function / working memory: Improvement in age-associated memory impairment with high-polyphenol spearmint extract (900 mg/day for 90 days)
- Attention and reaction time: Enhanced complex attention in healthy active adults with spearmint extract supplementation
Traditional / Supportive
- Digestive support: Carminative, antispasmodic — traditional use for flatulence, nausea, and dyspepsia across multiple cultures
- Respiratory complaints: Traditional use for cough, congestion, and cold symptoms
- Antioxidant support: High ORAC value and rosmarinic acid content provide significant free radical scavenging
Mechanism of Action
Anti-Androgenic Mechanism (Primary)
The anti-androgenic effect of spearmint operates through multiple, complementary pathways:
- Reduction of free testosterone: Consistently demonstrated in human trials; spearmint tea significantly decreases circulating free testosterone in women with PCOS and hirsutism
- Steroidogenic enzyme modulation: Animal studies (Kumar et al., 2008) demonstrated decreased expression of key steroidogenic enzymes:
- Cytochrome P450scc (cholesterol side-chain cleavage)
- Cytochrome P450C17 (17-alpha-hydroxylase)
- 3-beta-hydroxysteroid dehydrogenase (3-beta-HSD)
- 17-beta-hydroxysteroid dehydrogenase (17-beta-HSD)
- Steroidogenic acute regulatory protein (StAR)
- Androgen receptor expression
- Gonadotropin modulation: Increases LH and FSH levels, suggesting a central (hypothalamic-pituitary) component to the mechanism
- Hepatic androgen clearance: Proposed enhancement of hepatic processing and elimination of androgens
The net effect is a reduction in bioavailable androgens without suppressing total testosterone to the same degree, suggesting the mechanism is distinct from pharmaceutical anti-androgens like spironolactone or finasteride.
Key Bioactive Compounds
| Compound Class | Key Compounds | Concentration | Proposed Role |
|---|---|---|---|
| Phenolic acids | Rosmarinic acid and derivatives | Up to 88% of total phenolics; 7—118 mg/g dry weight | Major antioxidant; possible anti-androgenic contributor; neuroprotective |
| Monoterpenes | Carvone | 22—73% of essential oil | Distinguishing volatile; antispasmodic; antimicrobial |
| Monoterpenes | Limonene | 8—31% of essential oil | Anti-inflammatory; antioxidant |
| Phenolic acids | Salvianolic acids, caffeoylquinic acids | Minor components | Antioxidant synergy |
| Flavonoids | Naringenin, naringin, quercetin | Variable | Antioxidant; possible hormonal modulation |
| Other volatiles | 1,8-cineole, menthone, beta-caryophyllene | Minor | Aromatic; minor pharmacological contributions |
Cognitive Enhancement Mechanism
The cognitive benefits of spearmint extract are attributed primarily to its high polyphenol content, particularly rosmarinic acid:
- Antioxidant neuroprotection: Rosmarinic acid scavenges reactive oxygen species in neural tissue
- Anti-inflammatory effects: Reduction of neuroinflammation via inhibition of COX and LOX pathways
- Cholinergic modulation: Rosmarinic acid has demonstrated acetylcholinesterase inhibitory activity in vitro
- BDNF upregulation: Polyphenols may support brain-derived neurotrophic factor expression
Clinical Evidence Summary
Anti-Androgenic Effects: Key Clinical Trials
Akdogan et al. 2007 — Pilot Study in Hirsutism
“Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism”
| Parameter | Detail |
|---|---|
| Citation | Akdogan M, Tamer MN, Cure E, et al. Phytother Res. 2007;21(5):444-447 |
| PMID | 17310494 |
| Design | Uncontrolled pilot study |
| Participants | 21 women with hirsutism (12 PCOS, 9 idiopathic) |
| Intervention | Spearmint tea (1 cup, steeped with dried M. spicata), twice daily for 5 days during the follicular phase |
| Primary outcomes | Serum free testosterone, total testosterone, DHEAS, LH, FSH, estradiol |
Results:
- Free testosterone: Significantly decreased (p < 0.05)
- LH: Significantly increased (p < 0.05)
- FSH: Significantly increased (p < 0.05)
- Estradiol: Significantly increased (p < 0.05)
- Total testosterone: No significant change
- DHEAS: No significant change
Limitations: No placebo control; very short duration (5 days); hirsutism was not clinically scored at endpoint. This was a proof-of-concept study demonstrating hormonal changes only.
Significance: First human study to demonstrate spearmint’s anti-androgenic hormonal effects, providing the rationale for the subsequent RCT.
Grant 2010 — Randomized Controlled Trial in PCOS
“Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial”
| Parameter | Detail |
|---|---|
| Citation | Grant P. Phytother Res. 2010;24(2):186-188 |
| PMID | 19585478 |
| Design | Two-center, 30-day, randomized controlled trial |
| Participants | 42 women with PCOS (Rotterdam criteria), ages 19—42 (mean 25.5 years), all with visible hirsutism |
| Intervention | Spearmint tea (brewed with dried M. spicata) twice daily for 30 days vs. placebo herbal tea |
| Assessments | Serum androgens and gonadotropins at days 0, 15, and 30; Ferriman-Gallwey hirsutism score; modified DQLI (Dermatology Quality of Life Index) |
Results:
- Free testosterone: Significantly decreased in spearmint group vs. placebo (p < 0.05)
- Total testosterone: Significantly decreased in spearmint group vs. placebo (p < 0.05)
- LH: Significantly increased (p < 0.05)
- FSH: Significantly increased (p < 0.05)
- Subjective hirsutism (modified DQLI): Significantly improved in spearmint group (p < 0.05)
- Objective hirsutism (Ferriman-Gallwey score): No significant difference between groups (p = 0.12)
Key interpretation: The hormonal changes were robust and consistent with the pilot study, but the lack of objective hirsutism improvement is expected given the biology of hair growth — androgen-dependent follicular changes require many months to manifest visually. Grant noted that the 30-day study duration was insufficient to assess clinical hair reduction and proposed longer future studies.
Strengths: Randomized design; placebo control; two-center recruitment; hormonal endpoints well-measured.
Limitations: Small sample size (n = 42); short duration (30 days); no blinding details reported; single publication from one research group.
Preclinical Support: Animal Studies
| Study | Model | Key Finding |
|---|---|---|
| Akdogan et al. 2004 (PMID: 15302514) | Male Wistar rats | Spearmint tea decreased plasma testosterone and increased LH/FSH in dose-dependent manner; testicular histological changes observed |
| Kumar et al. 2008 (PMID: 18804513) | Male rats | Spearmint induced hypothalamic oxidative stress and downregulated steroidogenic enzymes (P450scc, P450C17, 3-beta-HSD, 17-beta-HSD, StAR) and androgen receptor |
| Sadeghi Ataabadi et al. 2017 (PMID: 29399556) | PCOS rat model | Spearmint essential oil reversed hormonal and folliculogenesis disturbances in experimentally induced PCOS |
Cognitive Enhancement: Clinical Trials
Herrlinger et al. 2018 — Working Memory in Age-Associated Memory Impairment
“Spearmint extract improves working memory in men and women with age-associated memory impairment”
| Parameter | Detail |
|---|---|
| Citation | Herrlinger KA, Nieman KM, Sanoshy KD, et al. J Altern Complement Med. 2018;24(1):37-47 |
| PMID | 29314866 |
| Design | Double-blind, placebo-controlled, parallel-group RCT |
| Participants | 90 men and women with age-associated memory impairment (67% female; mean age 59.4 years) |
| Intervention | 900 mg/day, 600 mg/day, or placebo spearmint extract (high in rosmarinic acid and polyphenols; Neumentix brand) for 90 days |
Results:
- Quality of working memory: 15% improvement with 900 mg/day vs. placebo (p = 0.0469)
- Spatial working memory accuracy: 9% improvement with 900 mg/day vs. placebo (p = 0.0456)
- 600 mg/day: No significant improvement vs. placebo
- Sleep quality: Improved in 900 mg/day group (secondary endpoint)
- Dose-response: Significant dose-response effect between 900 mg and 600 mg groups
Note: Study funded by Kemin Industries, the manufacturer of the Neumentix spearmint extract.
Falcone et al. 2019 — Attention in Healthy Active Adults
“The attention-enhancing effects of spearmint extract supplementation in healthy men and women”
| Parameter | Detail |
|---|---|
| Citation | Falcone PH, Nieman KM, Tribby AC, et al. Nutr Res. 2019;64:24-38 |
| PMID | 30802720 |
| Design | Randomized, double-blind, placebo-controlled, parallel trial |
| Participants | 142 healthy, recreationally active men and women |
| Intervention | 900 mg/day proprietary spearmint extract vs. placebo for 90 days |
Results:
- Complex attention: Significant improvement at day 7 vs. placebo
- Shifting attention test: Significant improvement
- Sustained attention (4-part continuous performance test): Significant improvement
- Agility: Improved reactive agility performance
Note: Also funded by Kemin Industries. Extends the cognitive findings from older adults to a younger, active population.
Evidence Summary Table
| Indication | Study Quality | Number of Trials | Overall Finding |
|---|---|---|---|
| Anti-androgenic (PCOS/hirsutism) | 1 RCT + 1 pilot + animal studies | 2 human + 3 animal | Consistent free testosterone reduction; LH/FSH increase; no objective hirsutism improvement in 30 days |
| Cognitive — working memory | 1 DB-RCT | 1 (n=90) | 15% improvement at 900 mg/day; dose-dependent |
| Cognitive — attention | 1 DB-RCT | 1 (n=142) | Significant improvement in complex and sustained attention |
| Digestive | Traditional use only | 0 clinical trials | No formal clinical evidence; traditional carminative use |
Safety Profile
Overall Safety Assessment
Spearmint is generally recognized as safe (GRAS) by the US FDA as a food flavoring and is consumed worldwide as a common beverage tea. The safety profile is exceptionally favorable compared to pharmaceutical anti-androgens.
Contraindications
- Known hypersensitivity to spearmint or other Lamiaceae family members (basil, rosemary, sage, thyme, lavender)
- Iron deficiency anemia (theoretical): Tannin and polyphenol content may reduce non-heme iron absorption when consumed with meals
- Severe kidney disease: Large amounts may theoretically exacerbate renal conditions (based on limited preclinical data; clinical relevance uncertain)
- Severe liver disease: Same precautionary reasoning as kidney disease
Drug Interactions
- No clinically significant drug interactions have been documented for spearmint tea at standard doses
- Sedative medications (theoretical): Spearmint may have mild sedative properties; additive effects with CNS depressants are theoretically possible but not clinically reported
- Iron supplements: Polyphenol/tannin content may reduce iron absorption if taken simultaneously; separate by 2 hours
- Anti-androgenic drugs (spironolactone, finasteride, flutamide): Theoretical additive anti-androgenic effect; clinical significance unknown but worth monitoring
Side Effects
- At typical tea doses (2 cups/day): Essentially no side effects reported in clinical trials
- Possible: Mild heartburn or gastroesophageal reflux (relaxation of lower esophageal sphincter, as with other mints)
- Rare: Allergic contact dermatitis (topical); oral allergic reactions in mint-sensitive individuals
- Overconsumption: Nausea, vomiting, stomach irritation reported only with excessive amounts
Pregnancy and Lactation
- Pregnancy Category C: Insufficient human data. Large doses of spearmint are traditionally cautioned against in pregnancy due to possible uterotonic effects. Moderate consumption as a culinary herb or occasional tea is generally considered acceptable, but therapeutic doses (2+ cups daily for anti-androgenic effect) should be avoided during pregnancy. The anti-androgenic mechanism is of particular theoretical concern during fetal development.
- Lactation: Insufficient data. No adverse effects reported at culinary doses. Therapeutic anti-androgenic doses have not been studied during lactation.
Comparison with Pharmaceutical Anti-Androgens
| Parameter | Spearmint Tea | Spironolactone | Finasteride |
|---|---|---|---|
| Anti-androgenic potency | Mild-moderate | Strong | Strong |
| Side effects | Minimal | Hyperkalemia, menstrual irregularities, fatigue | Sexual dysfunction, teratogenicity |
| Pregnancy safety | Category C (caution) | Category X (contraindicated) | Category X (contraindicated) |
| Monitoring required | None | Potassium, blood pressure | None routine, but liver enzymes |
| Availability | OTC, food-grade | Prescription | Prescription |
Clinical Dosage
Spearmint Tea (Most Studied Form)
| Parameter | Recommendation |
|---|---|
| Preparation | 1—2 teaspoons (1—2 g) dried spearmint leaves per cup (250 mL); pour boiling or near-boiling water (93—100 C); steep covered for 5—10 minutes |
| Dose | 2 cups daily (total approximately 2—5 g dried leaf per day) |
| Timing | One cup morning, one cup evening (as per clinical trial protocols) |
| Duration | Minimum 30 days for hormonal effects (per Grant 2010); likely 3—6 months needed for clinical improvement in hirsutism |
| Form used in trials | Dried Mentha spicata leaf steeped as tea |
Spearmint Extract (Cognitive Indications)
| Parameter | Recommendation |
|---|---|
| Studied product | Neumentix (Kemin Industries) — high-polyphenol spearmint extract standardized to rosmarinic acid and total phenolics |
| Dose | 900 mg/day (two capsules with breakfast) |
| Duration | 90 days in clinical trials |
| Note | 600 mg/day was not effective; 900 mg/day is the minimum effective dose based on available evidence |
Forms and Preparations
| Form | Typical Dose | Evidence Level | Notes |
|---|---|---|---|
| Dried leaf tea | 2—5 g/day (as 2 cups tea) | RCT evidence for PCOS/hirsutism | Most studied; simple and accessible |
| Standardized extract capsules | 900 mg/day | RCT evidence for cognitive function | Neumentix is the only studied extract product |
| Essential oil | Not recommended internally | Preclinical only | Internal use not supported by clinical evidence |
| Tincture | No clinical data | Traditional use only | Not studied for anti-androgenic effect |
Clinical Pearls
- Hair growth cycle: Even with effective androgen reduction, visible improvement in hirsutism requires 6—12 months due to the anagen-telogen hair cycle; patients should be counseled on realistic timelines
- Consistency matters: Daily consumption is important; the anti-androgenic effect likely depends on sustained exposure
- Quality: Use pure Mentha spicata leaf; do not substitute peppermint (Mentha x piperita), which has a different phytochemical profile and lacks the same anti-androgenic evidence
- Combination approaches: Spearmint tea can be used alongside other evidence-based PCOS interventions (inositol, metformin, lifestyle modifications) — no contraindications to combination use have been reported
Sources
- Grant P. Spearmint herbal tea has significant anti-androgen effects in polycystic ovarian syndrome. A randomized controlled trial. Phytother Res. 2010;24(2):186-188. PMID: 19585478
- Akdogan M, Tamer MN, Cure E, et al. Effect of spearmint (Mentha spicata Labiatae) teas on androgen levels in women with hirsutism. Phytother Res. 2007;21(5):444-447. PMID: 17310494
- Akdogan M, Ozguner M, Kocak A, Oncu M, Cicek E. Effects of peppermint teas on plasma testosterone, follicle-stimulating hormone, and luteinizing hormone levels and testicular tissue in rats. Urology. 2004;64(2):394-398. PMID: 15302514
- Kumar V, Kural MR, Pereira BM, Roy P. Spearmint induced hypothalamic oxidative stress and testicular anti-androgenicity in male rats. Food Chem Toxicol. 2008;46(12):3563-3570. PMID: 18804513
- Sadeghi Ataabadi M, Alaee S, Bagheri MJ, Bahmanpoor S. Role of essential oil of Mentha spicata (spearmint) in addressing reverse hormonal and folliculogenesis disturbances in a polycystic ovarian syndrome in a rat model. Adv Pharm Bull. 2017;7(4):651-654. PMID: 29399556
- Herrlinger KA, Nieman KM, Sanoshy KD, et al. Spearmint extract improves working memory in men and women with age-associated memory impairment. J Altern Complement Med. 2018;24(1):37-47. PMID: 29314866
- Falcone PH, Nieman KM, Tribby AC, et al. The attention-enhancing effects of spearmint extract supplementation in healthy men and women. Nutr Res. 2019;64:24-38. PMID: 30802720
- Mahendran G, Rahman LU. Ethnomedicinal, phytochemical and pharmacological updates on peppermint (Mentha x piperita L.) — a review. Phytother Res. 2020;34(9):2088-2139. PMC: 9019422
- Nouri H, Azin M, Khoshvaghti A. The traditional uses, phytochemistry and pharmacology of spearmint (Mentha spicata L.): A review. J Ethnopharmacol. 2021;278:114266. PMID: 34087400
- Bardaweel SK, Bakchoul MM, AlSalamat HA, et al. Association of herbal tea and follicle-stimulating hormone, anthropometric parameters, and fasting blood glucose levels among PCOS women: a systematic review and meta-analysis. Clin Nutr Res. 2024;13(3):201-214
- Moreno L, Bello R, Beltran B, et al. A descriptive overview of the medical uses given to Mentha aromatic herbs throughout history. Foods. 2020;9(12):1839. PMC: 7767097
Connections
- Compare with Peppermint — closely related species but pharmacologically distinct; peppermint is menthol-dominant and used for IBS/digestive complaints, while spearmint is carvone-dominant and used for anti-androgenic effects; they should not be used interchangeably for therapeutic purposes
- Compare with Vitex / Chasteberry — both used in women’s hormonal health but through different mechanisms; Vitex acts via dopamine D2 receptor agonism to reduce prolactin, while spearmint directly reduces free testosterone; they address different aspects of the PCOS hormonal picture and could theoretically be complementary
- Compare with Red Clover — both are women’s health herbs with hormonal activity; Red Clover contains phytoestrogens (isoflavones) for menopausal symptoms, while spearmint is anti-androgenic; different patient populations and indications
- Compare with Saw Palmetto — both have anti-androgenic mechanisms involving 5-alpha-reductase and steroidogenic enzyme modulation; saw palmetto is used for BPH in men, while spearmint is used for hyperandrogenism in women; the mechanistic parallel is notable despite the different clinical contexts
Related Herbs
Peppermint
*Mentha x piperita*
See full monograph below.
Red Clover
Trifolium pratense
Red Clover is a significant source of isoflavones (formononetin, biochanin A, genistein, daidzein) used primarily for menopausal hot flashes. Unlike soy isoflavones, Red Clover contains higher proportions of the methylated isoflavones formononetin and biochanin A. Meta-analyses show a statistically significant reduction in hot flash frequency (-1.73/day vs. placebo), with best results at doses of 80+ mg isoflavones/day for 12+ weeks. However, formal European regulatory recognition is limited -- there is no Commission E or ESCOP monograph specifically for menopausal use, and the EMA assessment is not as developed as for Black Cohosh or Vitex. Promensil is the most studied commercial product. Safety appears acceptable for up to 2 years, but uncertainty persists regarding use in hormone-sensitive cancers.
Saw Palmetto
Serenoa repens
Saw palmetto is the most extensively studied phytotherapeutic for BPH worldwide. The hexane extract (Permixon) has EMA "well-established use" status and has shown efficacy comparable to finasteride and tamsulosin in European trials. However, two major US trials (STEP, CAMUS) using ethanol/CO2 extracts found no benefit over placebo. This divergence -- driven by extract type, regulatory philosophy, and trial design -- represents the most significant EU-US split in phytotherapy evidence assessment.